KCNA3 and Alzheimer disease: Both KCa3.1 and Kv1.3 channels attracted interest as pharmacological targets for inhibiting detrimental microglia action in different pathological conditions, including spinal cord injury (Bouhy et al., 2011), ischemia (Y. J. Chen, Raman, Bodendiek, O'Donnell, & Wulff, 2011; Y. J. Chen et al., 2015), AD as well as cerebrovascular and traumatic brain injuries (Dale, Staal, Eder, & Moller, 2016; Maezawa et al., 2018; Maezawa, Jenkins, Jin, & Wulff, 2012; Nguyen et al., 2017).